Mustafa Kosecik1, Pinar Dervisoglu2, Mehmet Koroglu3, Pinar Isguven4, Bahri Elmas5, Tayfur Demiray3, Mustafa Altindis3. 1. Department of Pediatric Cardiology, School of Medicine, Sakarya University, Sakarya, Turkey. Electronic address: mustafakosecik@yahoo.com. 2. Department of Pediatric Cardiology, School of Medicine, Sakarya University, Sakarya, Turkey. 3. Department of Medical Microbiology, School of Medicine, Sakarya University, Sakarya, Turkey. 4. Department of Pediatric Endocrinology, School of Medicine, Sakarya University, Sakarya, Turkey. 5. Department of Pediatrics, School of Medicine, Sakarya University, Sakarya, Turkey.
Abstract
OBJECTIVE: Soluble urokinase plasminogen activator receptor (suPAR) has emerged as a relatively new biomarker that reflects increased inflammatory status and been associated with cardiovascular risk. We wanted to investigate the predictive value and usefulness of suPAR as an inflammatory biomarker in obese children. METHODS AND RESULTS: Of the total 136 participants, 76 (36 male, 40 female) were in obese group and 60 (24 male, 36 female) were in control group. The median age was 12.05 (6.16-17.30) years old for obese group, and 12.83 (8.00-16.75) years old for control group. Obese children had statistically significantly higher heart rate, systolic and diastolic blood pressure, EAT and LV mass than control group (p<0.01). The median suPAR level in obese group was not statistically different than in control group (0.54 vs. 0.59, p=0.26). The median hsCRP level in obese group was found statistically significantly higher than in control group (1.97 vs. 0.41, p<0.01). A significant positive correlation between hsCRP and BMI in the obese participants was found (r=0.45, p<0.01), but not a relationship between suPAR and BMI (r=-0.21, p>0.05). CONCLUSION: Our research did not demonstrate the usefulness of suPAR as an inflammatory biomarker and a predictive value for future atherosclerosis in obese children. Further studies with larger sample size are required to determine whether suPAR is useful as an inflammatory biomarker in childhood obesity.
OBJECTIVE: Soluble urokinase plasminogen activator receptor (suPAR) has emerged as a relatively new biomarker that reflects increased inflammatory status and been associated with cardiovascular risk. We wanted to investigate the predictive value and usefulness of suPAR as an inflammatory biomarker in obesechildren. METHODS AND RESULTS: Of the total 136 participants, 76 (36 male, 40 female) were in obese group and 60 (24 male, 36 female) were in control group. The median age was 12.05 (6.16-17.30) years old for obese group, and 12.83 (8.00-16.75) years old for control group. Obesechildren had statistically significantly higher heart rate, systolic and diastolic blood pressure, EAT and LV mass than control group (p<0.01). The median suPAR level in obese group was not statistically different than in control group (0.54 vs. 0.59, p=0.26). The median hsCRP level in obese group was found statistically significantly higher than in control group (1.97 vs. 0.41, p<0.01). A significant positive correlation between hsCRP and BMI in the obeseparticipants was found (r=0.45, p<0.01), but not a relationship between suPAR and BMI (r=-0.21, p>0.05). CONCLUSION: Our research did not demonstrate the usefulness of suPAR as an inflammatory biomarker and a predictive value for future atherosclerosis in obesechildren. Further studies with larger sample size are required to determine whether suPAR is useful as an inflammatory biomarker in childhood obesity.
Authors: Darcy K Weidemann; Alison G Abraham; Jennifer L Roem; Susan L Furth; Bradley A Warady Journal: Am J Kidney Dis Date: 2020-01-24 Impact factor: 8.860
Authors: Franz Schaefer; Howard Trachtman; Elke Wühl; Marietta Kirchner; Salim S Hayek; Ali Anarat; Ali Duzova; Sevgi Mir; Dusan Paripovic; Alev Yilmaz; Francesca Lugani; Klaus Arbeiter; Mieczyslaw Litwin; Jun Oh; Maria Chiara Matteucci; Jutta Gellermann; Simone Wygoda; Augustina Jankauskiene; Günter Klaus; Jiri Dusek; Sara Testa; Aleksandra Zurowska; Alberto Caldas Afonso; Melissa Tracy; Changli Wei; Sanja Sever; William Smoyer; Jochen Reiser Journal: JAMA Pediatr Date: 2017-11-06 Impact factor: 16.193